Filamentous Fungi Pathway Balancing Patents: Top Companies & Trends 2026
Filamentous Fungi Pathway Balancing Patents: Who Holds the Claim Space
Concentrated at the top. The five leading assignees hold 74.8% of all 103 records in scope, and the ten leading assignees hold 99.0% — almost nothing sits outside that group. Publications rose from 3 in 2017 to a peak of 9 in 2022, then declined to 0 by 2024 — a -100% move over that three-year span. Because publication typically lags filing by roughly 18 months, the 2025-2026 tail understates real activity and should not be read as a slowdown on its own.
- 1BASF ENZYMES LLC38
- 2SYNGENTA PARTICIPATIONS AG17
- 3DSM IP ASSETS BV10
- 4EVOLVA SA(CH)6
- 5DSM SINOCHEM PHARMA NETHERLANDS6
See the full filamentous fungi pathway balancing analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who are the leading patent holders in filamentous fungi pathway balancing?
The field is heavily concentrated: the five leading assignees together hold 74.8% of the 103 records in scope, and the ten leading assignees hold 99.0%. One assignee alone accounts for 38 records, well ahead of the company in fifth place at 6. This means most of the useful competitive intelligence in this space comes from watching a small group of companies rather than tracking a broad field of independent filers.
Is patent filing activity in this area growing or shrinking?
Published filings rose from 3 in 2017 to a peak of 9 in 2022, then fell to 0 by 2024, a -100% move over that three-year span. However, patent publication typically lags the actual filing date by around 18 months, so the 2025-2026 figures in any dataset are still incomplete and should not be read as proof the field has gone quiet. The safest reading is that activity peaked around 2022 and the true 2024-2026 trend will only be clear once later publications catch up.
What technology areas does filamentous fungi pathway balancing patent activity cover?
Every record in this dataset carries a core genetic-engineering classification (C12N), but the largest overlays are fermentation and enzymatic synthesis (C12P, 67.0% of records) and enzyme/DNA measuring and testing methods (C12Q, 58.3%). Smaller but notable shares appear in medicinal preparations, sugars and nucleic acids, food, baking and brewing applications. Because a single filing can carry several classifications, these percentages add up to more than 100% of the record total.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Filamentous Fungi Pathway Balancing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.